Compare Goldman Sachs Group Inc (GS) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Group Inc vs Hinge Health Inc. Class A Common Stock — how do they compare? Goldman Sachs Group Inc trades at $877.8 (market cap $259.70B), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B). The key difference: Goldman Sachs Group Inc is far larger — about 30.6× Hinge Health Inc. Class A Common Stock's market cap, and Goldman Sachs Group Inc pays a 2.24% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Goldman Sachs Group Inc for 100 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| GS | HNGE | |
|---|---|---|
Market Cap | $259.70B | $8.48B |
Volume | 4,939,526 | 879,799 |
Sector | Financials | Health |
52-Week High | $1.15K | $105.14 |
52-Week Low | $744.60 | $31.17 |
Typical Hold Time | 100 Days | 0 Days |
Enterprise Value | $263.03B | $8.10B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $893.95, down 0.15% with bearish technical signals but strong fundamental performance. The stock shows consistent earnings beats with Q3 2026 EPS of $17.01 exceeding expectations by 32%. Revenue growth accelerated to $58.28B in 2025 with net income margin improving to 29.46%. Recent news highlights the company's focus on expanding its $70B revenue base and AI initiatives.
GS presents a compelling value case with a P/E of 13.77 below industry averages, supported by 40% analyst buy ratings and a $1,130 consensus price target. However, negative operating cash flow trends and bearish technical indicators suggest near-term volatility. The dividend yield of approximately 0.56% provides income support while the company executes its growth strategy.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
